2. Metabolic Enzyme/Protease Apoptosis NF-κB Immunology/Inflammation
  3. TrxR Glutathione Peroxidase Ferroptosis Reactive Oxygen Species (ROS)
  4. Platinum(IV) Prodrug-1

Platinum (IV) Prodrug-1 is a Pt (IV) prodrug and selective TrxR1 inhibitor. Platinum (IV) Prodrug-1 induces ferroptosis (Ferroptosis) by depleting glutathione, accumulating intracellular lipid peroxides, and inactivating Glutathione peroxidase 4. Platinum (IV) Prodrug-1 triggers endoplasmic reticulum stress and immunogenic cell death via excessive accumulation of intracellular ROS. Platinum (IV) Prodrug-1 exhibits anticancer activity against both Cisplatin (HY-17394)-sensitive and Cisplatin-resistant triple-negative breast cancer cells. Platinum (IV) Prodrug-1 can be used for the research of triple-negative breast cancer.

For research use only. We do not sell to patients.

Platinum(IV) Prodrug-1

Platinum(IV) Prodrug-1 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Platinum(IV) Prodrug-1 Related Antibodies

Top Publications Citing Use of Products

View All TrxR Isoform Specific Products:

View All Isoforms
TrxR1 TrxR2

View All Glutathione Peroxidase Isoform Specific Products:

View All Isoforms
GPX1 GPX4

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Platinum (IV) Prodrug-1 is a Pt (IV) prodrug and selective TrxR1 inhibitor. Platinum (IV) Prodrug-1 induces ferroptosis (Ferroptosis) by depleting glutathione, accumulating intracellular lipid peroxides, and inactivating Glutathione peroxidase 4. Platinum (IV) Prodrug-1 triggers endoplasmic reticulum stress and immunogenic cell death via excessive accumulation of intracellular ROS. Platinum (IV) Prodrug-1 exhibits anticancer activity against both Cisplatin (HY-17394)-sensitive and Cisplatin-resistant triple-negative breast cancer cells. Platinum (IV) Prodrug-1 can be used for the research of triple-negative breast cancer[1].

IC50 & Target[1]

TrxR1

 

GPX4

 

In Vitro

Platinum(IV) Prodrug-1 (Compound 6b) (2.5-5 μM; 24 h) induces concentration-dependent mitochondrial membrane potential reduction and activates the mitochondrial apoptosis pathway in Cisplatin-resistant MDA-MB-231/CDDP cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Platinum(IV) Prodrug-1 Related Antibodies
In Vivo

Platinum (IV) Prodrug-1 (7.2 mg/kg; intravenous injection; once every 2 days; for 21 consecutive days) exhibits potent in vivo antitumor activity in BALB/c mice inoculated with 4T1 triple-negative breast cancer (TNBC), achieving a tumor growth inhibition (TGI) rate of 76.8%, while potently activating the antitumor immune response[1].
Platinum (IV) Prodrug-1 (7.2 mg/kg; intravenous injection; once every 2 days; for 21 consecutive days) exhibits potent in vivo anti-tumor activity in cisplatin-sensitive MDA-MB-231 triple-negative breast cancer (TNBC) xenograft-bearing BALB/c nude mice, with a tumor growth inhibition (TGI) rate of 73.8%, and no organ toxicity is observed[1].
Platinum (IV) Prodrug-1 (7.2 mg/kg; intravenous injection; once every 2 days; for 21 consecutive days) exhibits potent in vivo antitumor activity in cisplatin-resistant MDA-MB-231/CDDP triple-negative breast cancer (TNBC) xenograft-bearing BALB/c nude mice, with a tumor growth inhibition (TGI) rate of 66.3%, and no organ toxicity is observed[1].
Platinum (IV) Prodrug-1 (7.2 mg/kg; intravenous injection; once every 2 days; for 14 consecutive days) effectively inhibits lung metastasis of 4T1 triple-negative breast cancer (TNBC) cells in BALB/c mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c (female, 4 weeks old, ~20 g, subcutaneous inoculation of 4T1 murine breast cancer cells)[1]
Dosage: 7.2 mg/kg
Administration: i.v.; once every 2 days; 21 days
Result: Achieved a tumor growth inhibition (TGI) rate of 76.8%.
Showed no significant body weight loss in treated mice.
Increased proportions of tumor-infiltrating lymphocytes: CD3+ T cells (23.46%), CD3+CD4+ T cells (14.40%), and CD3+CD8+ T cells (8.85%).
Increased CD80+CD86+ dendritic cells (56.78%) relative to control.
Elevated serum levels of proinflammatory cytokines TNF-α, IFN-γ, and IL-6 significantly compared to other treatment groups.
Increased levels of the ICD marker CRT and ER stress marker CHOP in tumor tissue via immunofluorescence staining.
Animal Model: BALB/c nude (female, 4−5 weeks old, ~18 g, subcutaneous inoculation of MDA-MB-231 human breast cancer cells)[1]
Dosage: 7.2 mg/kg
Administration: i.v.; once every 2 days; 21 days
Result: Achieved a tumor growth inhibition (TGI) rate of 73.8%.
Showed no significant body weight loss in treated mice.
Downregulated Ki67, TrxR1, and GPX4 expression significantly in tumor tissue relative to control and other treatment groups.
Showed no morphological alterations or adverse effects in major organs (heart, liver, spleen, lung, kidney) via H&E staining.
Molecular Weight

859.94

Formula

C26H26Cl3F6N3O4Pt
SMILES

O=C(CCCC(O[Pt]([NH3])(Cl)(Cl)([NH3])Cl)=O)N1C/C(C(/C(C1)=C/C2=CC(C(F)(F)F)=CC=C2)=O)=C\C3=CC=CC(C(F)(F)F)=C3
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Platinum(IV) Prodrug-1 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Platinum(IV) Prodrug-1TrxRGlutathione PeroxidaseFerroptosisReactive Oxygen Species (ROS)Thioredoxin ReductaseferroptosisThioredoxin reductase 1endoplasmic reticulum stresstriple-negative breast cancerTrxR1GSTreactive oxygen speciescatalaseTrxR2immunogenic cell deathInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Platinum(IV) Prodrug-1
Cat. No.:
HY-183544
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.